PDCD1 and neoplasm: For instance, due to the tumor’s evasion of the immune system, Ipilimumab, a CTLA-4 inhibitor, has enabled 21% of patients to survive beyond 10 years, and PD-1 inhibitors assist 30% of patients with advanced cancer in achieving survival beyond 5 years [81, 82].